SRTTD July 30, 2010 Brooks Adams Executive Director & President

1. Accelerating Commercialization in Nanobiotechnology SRTTD July 30, 2010 Brooks Adams Executive Director & President

2. Outline • COIN • The opportunity • COIN’s role • Working together

3. COIN We promote innovation & commercialization in nanobiotechnology & nanomedicine to enable future economic growth & improve human life.

4. Key facts • Nonprofit 501c3 launched June 2009 • $2.6 million funds committed • 4 full-time staff • Outsource finance, marketing, & IT • University intern program (4 - 5) • 8 Board members & 6 on SAB • Annual operating budget ~ $800K to 1MM • Based in Triangle; frequently in Triad & Charlotte and beyond

5. The opportunity “Human health has always been determined on the nanometer scale…where the structure & properties of the machines of life work in every one of the cells in every living thing. The practical impact of nanosciences on human health will be huge.” Dr. Richard Smalley, Nobel Laureate

6. Nanobiotechnology • Application of nanotechnology materials, tools, & processes in the life sciences & medicine: • Commercial applications: • Therapeutics & diagnostics • Medical technology & devices • Medical/life science research • Non human health-care related Versatile structure of carbon nanotubes enables use for variety of tasks in the body

7. The promise & challenge • Nanotech is a tool box not an industry • Many potential high value applications • Nanotech centers are forming globally & industry clusters grow around them • Requisite capabilities/resources: • Research, infrastructure, talent, money, & a conducive business environment are needed • A few major centers will develop “A Roadmap for Nanotechnology in NC’s 21st Century Economy,” March 2006

8. Nanobiotech global market • 2009 nanomedicine healthcare market largest in N America at $4.75 billion followed by Europe at $3.65 billion • Nano-enabled drug delivery largest segment with expected CAGR of 21.7% to ~ $16 billion by 2014 • Biocompatible implants & coatings and diagnostics estimated growth of 42% & 21.8%, respectively through 2014 • Global clusters: US, Singapore, Canada, Australia, Germany, China, UK, & Israel • US hubs: Boston, San Francisco, Houston, & RTP • US academic centers of excellence: NC, Mass., California, Ohio, & Texas Sources: Business Insights (Jan 2010), Pew Charitable Trusts, COIN database

9. Nanomedicine patents . Provided by Wake Forest Univ. Center for Translational Nanomedicine

10. Site-specific, targeted delivery Kam Leong, Duke University

11. Tissue engineering Kam Leong, Duke University

12. Vision for NC • Assets to succeed lie in Charlotte, Triad, & Triangle • Mix of nanotech research activity, medical centers, related large/emerging companies, and investors • To be nationally competitive, must promote projects in this corridor leveraging resident assets

13. NC nanobiotech ecosystem overview • Building from thriving, mature biotech industry & infrastructure, emerging nanobiotech sector is gaining rapid traction • NC strong in 3 of highest-growth nanotech sectors: • Medicine & healthcare • Tools/instruments • Materials • NC repeatedly recognized as leader in nanotech • 2009 survey (PEN) ranked NC 8th in US & Raleigh metro area 4th • 2009 US University Report & Rankings by Small Times placed NCSU 3rd in for nanotech commercialization and UNC-CH 5th & NCSU 10th for nanotech research • Positive political-business climate in support of biotech, low-cost of doing business, & high quality of life • NC Innovation Council

14. NC nanobiotech ecosystem overview • Industry • > 70 nanotech companies & 35 nanobiotech companies • > 280 US nanobiotech companies & additional 150 int’l nanobiotech companies • University & college resources • 30 university research centers • Two nanotech PhD programs (only 36 in world) • Among 1st in nation to offer nanotech associates degree • Supportive infrastructure • 7 major research parks across NC • 3 major nonprofit research institutes • 108 medical products CRO’s • Active, engaged VC & angel investment • NC Department of Commerce • NC Biotechnology Center • Centers of Innovation: COIN, ibiliti (med tech), Drug Discovery COI • NC Regional Partnerships • Community resources • CED • SBTDC

15. NC among nano-enabled drug delivery research university leaders • University Texas • Harvard University • MIT • University of Michigan • Johns Hopkins University • University of Illinois • Northwestern University • University of Washington • Purdue University • University of Utah • Georgia Institute of Technology • Washington University • University of Florida • University Pennsylvania • Cornell University • University of California at Berkeley • University of Massachusetts • University of California at San Francisco • University of Minnesota • NCI • Rice University • Ohio State University • University of California at Los Angeles • University of California at Santa Barbara • University Nebraska • University of North Carolina • University of Wisconsin • Penn State University • Massachusetts General Hospital • University of Kentucky • Stanford University • University of Maryland • University of Southern California • University of Pittsburgh • University of California at Davis • Emory University • SUNY Buffalo • University of California at San Diego • Northeastern University • Carnegie Mellon University • North Carolina State University • Vanderbilt University • Case Western Reserve University • Duke University • Brown University • CALTECH • Arizona State University • Columbia University • Rutgers State University • University of Delaware Source: COIN study (based on publications)

16. Leading NC nanobio companies • Liquidia: Series B VC funding, entering clinical trials • XinRay: Major partnership with Siemens • Pioneer Surgical Orthobiologics: Product on market • Biodelivery Sciences: Publicly traded; $56.69 MM market cap

17. COIN’s role COIN will helptransform ideas into commercial value.

18. Idea Develop Demo Quality Concept Plan Design Test Launch $ $

19. Burgeoning field with challenges • Shortage of qualified personnel • Education of workforce for future • Limited funding for early-stage innovation • Lack of pre-clinical/clinical testing guidance & facilities • Development of GMP capabilities / manufacturing scale up • Need for more: • Low-cost, flexible research space • Multidisciplinary research partnerships • Business development connections

20. COIN offers Innovators & entrepreneurs Resources to build relationships crucial for technology translation & business development Industry partners Single point of entry to nanobiotech sectors in NC and access to innovators & entrepreneurs Service providers Resources to develop nanobiotech project pipeline

21. COIN goals BUILD a community of practice of NC nanobiotech innovators & industry players focused on commercialization CONNECT innovators with promising nanobiotechnology with industry partners, resources, & collaborators GROW nanobiotech infrastructure in NC DRIVE new product development by reducing barriers to commercialization INCREASE the profile of NC nanobiotech activity globally

22. COIN programs • Events & seminars to build, connect, & inform the community: • Nanobiotech Executive Roundtable • Annual NC Nanotech Commercialization Conference: • Nanobio track Membership services including knowledge-rich web portal: • Business intelligence • RFP scouting service Innovation services that address specific obstacles to commercialization: • Grant writing • Incubation partners • Connections for pre-clinical testing

23. NC resources for pre-clinical testing

24. COIN clients & collaborators University researchers & tech transfer offices Pharma/biotech, specialty pharma, drug delivery companies Startups VC, angel, & public funding sources Equipment & software companies National nanobiotech research institutes Trade groups Law & accounting firms Economic development & policy makers

25. Working together “…to increase its share of nanotechnology activity nationally and internationally, the (Southeast) region needs to take specific steps in achieving a leadership role…with a focus on improved collaborations and increasing the number and growth of nanotechnology companies.” Source: “Connecting the Dots,” 2006, Southern Growth Policies Board, Georgia Tech, Oak Ridge Nat’l Lab

26. Creating a Southern nanotechnology strategy • Establish Southern Nanotech Network, a membership network to increase awareness of industry among South’s citizens, governments, & businesses and: • Offer opportunities for collaborative interaction between the public and private sectors • Identify policy advocates • Have each Southern Growth state put advancement of nanotech as a primary economic development goals • Develop/execute branding strategy for Southern nanotech to promote South’s assets within region, nationally & internationally • Coordinate collaborative trips to CA, NY, and MA to promote linkages between region & other major centers • Establish Southern Nanotechnology Institute, based on resources of Oak Ridge & others to: • Develop nanotech business incubation capacity for all Southern states • Increase funding opportunities for Southern institutions including state matching funds for SBIR and other federal grants with specific focus and development of equity funds for nanotech companies • Enhance availability & affordability of research tools • Develop survey of nano-equipment in region’s universities & research labs, so other users may gain access & subsidize their expenses through user agreements • Other considerations • More in-depth look at commercialization including development process, South’s market niches, & role of various funding sources • Explore opportunity/need for equipment cooperatives with vendors Source: “Connecting the Dots,” 2006, Southern Growth Policies Board, Georgia Tech, Oak Ridge Nat’l Lab

27. Summary • Technology knows no borders • Together we can accelerate commercialization in nanobiotechnology: • Foster nano-size solutions for life science research & medicine for the benefit of mankind • Bridge research community with business & funding sources to create R&D collaborations, new companies, and products

28. BROOKS ADAMS Executive Director & President brooks.adams@nc-coin.org Cell: 804-363-9574 Assistant: Clare Valcore / 919-782-1991, Ext. 302 1

29. Addendum

30. Major categories of nanomaterials Source: BCC research

31. Major categories of nanomaterials • Nanotools: • Device enabling viewing/manipulation of nanoscale objects • E.g., scanning probe microscope on market today • Nanodevices • Nanomachines to do useful work in medicine • E.g., nanorobots injected into blood to destroy cancer cells; medical nanosensors incorporating nanoengineered structures, e.g., spintronic sensors that incorporate nanoscale thin films or next generation nanomedical sensors, e.g., respiratory gas sensors (going soon to market) Source: BCC research